High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity,clinical presentation and implications for cardiovascular risk

Abstract

Measurement of high sensitivity C-reactive protein (hs-CRP), has been used in the assessment of disease activity in numerous rheumatic conditions including systemic lupus erythematosus (SLE). However, the utility of hs-CRP measurement in patients with lupus is uncertain. This study examined if hs-CRP can be used to assess disease activity, severity and cardiovascular risk in SLE. Serum samples from 601 visits of 213 SLE patients and 134 controls were analysed for hs-CRP by nephelometry. Detailed demographic data were obtained from all subjects and medication history and key laboratory parameters were collected. Disease activity was assessed using the SLEDAI. High sensitivity CRP was not associated with disease activity (SLEDAI), number of ACR SLE criteria or presence of any particular organ involvement. hs-CRP levels were significantly correlated with standard cardiovascular risk factors including body weight (P = 0.0002), hypertension (P = 0.001), and apolipoprotein A-I (P < 0.0001). Interestingly an inverse correlation was seen between hs-CRP levels and antimalarial use (P = 0.0018). Our results suggest that measurement of hs-CRP, though not valuable as marker of disease activity in SLE may be of some use in the assessment of cardiovascular risk. We speculate that antimalarials may help to reduce cardiovascular risk in patients with SLE.

Keywords

C-reactive protein hs-CRP SLE

Get full access to this article

View all access options for this article.

References

Volanakis JE. Human C-reactive protein: expression, structure, and function . Mol Immunol 2001; 38: 189-197 .

Gershov D , Kim S , Brot N , Elkon KB. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response: implications for systemic autoimmunity . J Exp Med 2000; 192: 1353-1364 .

Heuertz RM , Piquette CA , Webster RO. Rabbits with elevated serum C-reactive protein exhibit diminished neutrophil infiltration and vascular permeability in C5a-induced alveolitis . Am J Pathol 1993; 142: 319-328 .

Roman MJ , Shanker BA , Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus . N Engl J Med 2003; 349: 2399-2406 .

Rodriguez W , Kataranovski M , Rodic-Polic B , Mold C , DuClos TW. C-reactive protein treatment delays proteinuria and prolongs survival of NZB × NZW (B/W) mice . Arthritis Rheum 2003; 48(Suppl. 9): S200-S200 .

Ganapathi MK , Rzewnicki D , Samols D , Jiang SL , Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells . J Immunol 1991; 147: 1261-1265 .

Coste J , Spira A , Clerc D , Paolaggi JB. Prediction of articular destruction in rheumatoid arthritis: disease activity markers revisited . J Rheumatol 1997; 24: 28-34 .

Cantini F , Salvarani C , Olivieri I. Erythrocyte sedimentation rate and C-reactive protein in the diagnosis of polymyalgia rheumatica . Ann Intern Med 1998; 128: 873-874 .

Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis . J Rheumatol 1997; 24: 1477-1485 .

10.

Koenig W. Inflammation and coronary heart disease: an overview . Cardiol Rev 2001; 9: 31-35 .

11.

Nuttall SL , Heaton S , Piper MK , Martin U , Gordon C. Cardiovascular risk in systemic lupus erythematosus - evidence of increased oxidative stress and dyslipidaemia . Rheumatology (Oxford) 2003; 42: 758-762 .

12.

Mochizuki T , Aotsuka S , Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease . Respir Med 1999; 93: 95-101 .

13.

Zuniga R , Markowitz GS , Arkachaisri T , Imperatore EA , D’Agati VD , Salmon JE. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and FCgamma receptor type IIA alleles . Arthritis Rheum 2003; 48: 460-470 .

14.

Linares LF , Gomez-Reino JJ , Carreira PE , Morillas L , Ibero I. C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE) . Clin Rheumatol 1986; 5: 66-69 .

15.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

16.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1725-1725 .

17.

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH , SLE CoPSi. Derivation of the SLEDAI: a disease activity index for lupus patients . Arthritis & Rheumatism 1992; 35: 630-640 .

18.

Mennen LI , Balkau B , Royer B , et al. Microalbuminuria and markers of the atherosclerotic process: the D.E. S.I.R. study . Atherosclerosis 2001; 154: 163-169 .

19.

Diercks GF , van Boven AJ , Hillege HL et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study . Eur Heart J 2000; 21: 1922-1927 .

20.

Borch-Johnsen K , Feldt-Rasmussen B , Strandgaard S , Schroll M , Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease . Arterioscler Thromb Vasc Biol 1999; 19: 1992-1997 .

21.

Muscari A , Bastagli L , Poggiopollini G et al. Different associations of C-reactive protein, fibrinogen and C3 with traditional risk factors in middle-aged men . Int J Cardiol 2002; 83: 63-71 .

22.

Carroll MC. The role of complement and complement receptors in induction and regulation of immunity . Annu Rev Immunol 1998; 16: 545-568 .

23.

Asanuma Y , Oeser A , Shintani AK et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus . N Engl J Med 2003; 349: 2407-2415 .

24.

Bruce IN , Urowitz MB , Gladman DD , Ibanez D , Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study . Arthritis Rheum 2003; 48: 3159-3167 .

25.

Lloyd-Jones DM , Larson MG , Beiser A , Levy D. Lifetime risk of developing coronary heart disease . Lancet 1999; 353: 89-92 .

26.

Walldius G , Jungner I , Holme I , Aastveit AH , Kolar W , Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study . Lancet 2001; 358: 2026-2033 .

27.

Mukherjee D , Topol EJ. Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors . Arthritis Res Ther 2003; 5: 8-11 .

28.

Munro R , Morrison E , McDonald AG , Hunter JA , Madhok R , Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis . Ann Rheum Dis 1997; 56: 374-377 .